Skip to main content
NVDA-0.02%AAPL-0.17%GOOGL+0.59%MSFT-0.02%AMZN-0.02%TSM-1.68%SPCX+0.43%AVGO-0.97%META-0.04%TSLA+0.11%SKHY-5.20%MU+0.08%BRK-B+0.06%LLY-0.10%JPM-0.32%WMT-0.09%AMD-3.36%V-0.05%XOM+0.61%ASMLa-1.66%JNJ-0.27%INTC-5.57%MA-0.38%0700.HK-1.94%1398.HK+0.79%ORCL-5.23%ABBV+1.62%BAC-0.18%CSCO-1.82%CVX-0.50%COST-0.02%KO+0.32%LRCX-5.65%CAT-1.29%AP2d-1.55%0005.HK-0.78%AMAT-3.17%UNH-1.22%HSBA.L-1.30%DELL-5.35%PG+0.25%MS-1.22%GE-0.39%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.03%HD-1.53%0939.HK+1.66%GS-0.88%NZDJPY-2.59%AUDJPY-1.80%CHFJPY-1.61%NZDCAD-1.46%NZDUSD-1.44%EURNZD+1.43%GBPNZD+1.39%GBPJPY-1.21%EURJPY-1.21%USDJPY-1.18%CADJPY-1.15%NZDCHF-1.02%USDSEK+0.99%USDZAR+0.97%USDNOK+0.88%AUDNZD+0.81%EURSEK+0.79%EURZAR+0.77%USDTHB+0.72%GBPZAR+0.70%AUDCAD-0.68%EURNOK+0.67%AUDUSD-0.64%AUDDKK-0.62%EURAUD+0.60%CHFSEK+0.60%USDMXN+0.58%GBPAUD+0.58%AUDSGD-0.55%USDPLN+0.49%CHFNOK+0.48%USDCHF+0.45%CADCHF+0.44%NZDSGD-0.43%GBPTRY+0.41%EURCHF+0.40%GBPCHF+0.38%GBPHKD+0.32%NOKJPY-0.31%USDSGD+0.30%GBPMXN-0.28%EURPLN+0.28%SGDJPY+0.27%USDDKK+0.21%EURHKD-0.21%AUDCHF-0.20%USDILS+0.16%NZDMXN-0.16%USDTRY+0.11%USDCNH+0.11%CHFSGD-0.10%EURSGD+0.09%EURCNH-0.08%GBPCAD-0.08%PLNJPY+0.07%EURCAD-0.06%GBPUSD-0.04%EURUSD-0.04%USDCOP-0.04%AUDNOK+0.03%EURCZK-0.03%EURGBP+0.02%USDHKD+0.02%GBPSGD+0.02%USDCAD-0.01%EURDKK+0.01%UKOIL+6.49%USOIL+6.40%XPTUSD-6.24%GAGUSD-5.47%XAGUSD-5.47%HG1-4.78%GAUUSD-1.92%XAUUSD-1.92%XNGUSD+1.68%SUGAR0.00%S10.00%COFFEE0.00%BTCUSD-1.32%ETHUSD-0.21%USDTUSD-0.02%XRPUSD-2.96%SOLUSD-1.53%TRXUSDT+0.12%ZECUSDT-9.33%DOGEUSD-2.24%XMRUSDT+0.03%LINKUSD-1.68%XLMUSD-1.77%BCHUSDT-9.71%LTCUSD-1.57%UNIUSD-1.34%TONUSD+24.88%HBARUSDT-1.85%SUIUSD-3.99%TAOUSDT-5.72%AAVEUSD-2.22%DOTUSDT-1.47%ICPUSDT+1.08%ONDOUSDT-3.31%WLDUSDT-3.15%ATOMUSDT-2.16%ARBUSDT-1.88%JUPUSDT-2.53%INJUSDT-2.62%STXUSDT-4.53%FETUSDT-2.47%TIAUSDT-1.39%PYTHUSDT-1.26%SEIUSDT-6.02%IMXUSDT-3.85%WIFUSDT-4.89%GRTUSDT-3.53%OPUSDT-3.00%POLUSDT-4.85%IOTAUSDT-4.24%AXSUSDT-2.36%FARTCOINUSDT-3.35%EOSUSDT-2.29%DYDXUSDT-1.75%ORDIUSDT-1.01%GALAUSDT-3.65%NOTUSDT-2.97%RONINUSDT-2.64%NVDA-0.02%AAPL-0.17%GOOGL+0.59%MSFT-0.02%AMZN-0.02%TSM-1.68%SPCX+0.43%AVGO-0.97%META-0.04%TSLA+0.11%SKHY-5.20%MU+0.08%BRK-B+0.06%LLY-0.10%JPM-0.32%WMT-0.09%AMD-3.36%V-0.05%XOM+0.61%ASMLa-1.66%JNJ-0.27%INTC-5.57%MA-0.38%0700.HK-1.94%1398.HK+0.79%ORCL-5.23%ABBV+1.62%BAC-0.18%CSCO-1.82%CVX-0.50%COST-0.02%KO+0.32%LRCX-5.65%CAT-1.29%AP2d-1.55%0005.HK-0.78%AMAT-3.17%UNH-1.22%HSBA.L-1.30%DELL-5.35%PG+0.25%MS-1.22%GE-0.39%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.03%HD-1.53%0939.HK+1.66%GS-0.88%NZDJPY-2.59%AUDJPY-1.80%CHFJPY-1.61%NZDCAD-1.46%NZDUSD-1.44%EURNZD+1.43%GBPNZD+1.39%GBPJPY-1.21%EURJPY-1.21%USDJPY-1.18%CADJPY-1.15%NZDCHF-1.02%USDSEK+0.99%USDZAR+0.97%USDNOK+0.88%AUDNZD+0.81%EURSEK+0.79%EURZAR+0.77%USDTHB+0.72%GBPZAR+0.70%AUDCAD-0.68%EURNOK+0.67%AUDUSD-0.64%AUDDKK-0.62%EURAUD+0.60%CHFSEK+0.60%USDMXN+0.58%GBPAUD+0.58%AUDSGD-0.55%USDPLN+0.49%CHFNOK+0.48%USDCHF+0.45%CADCHF+0.44%NZDSGD-0.43%GBPTRY+0.41%EURCHF+0.40%GBPCHF+0.38%GBPHKD+0.32%NOKJPY-0.31%USDSGD+0.30%GBPMXN-0.28%EURPLN+0.28%SGDJPY+0.27%USDDKK+0.21%EURHKD-0.21%AUDCHF-0.20%USDILS+0.16%NZDMXN-0.16%USDTRY+0.11%USDCNH+0.11%CHFSGD-0.10%EURSGD+0.09%EURCNH-0.08%GBPCAD-0.08%PLNJPY+0.07%EURCAD-0.06%GBPUSD-0.04%EURUSD-0.04%USDCOP-0.04%AUDNOK+0.03%EURCZK-0.03%EURGBP+0.02%USDHKD+0.02%GBPSGD+0.02%USDCAD-0.01%EURDKK+0.01%UKOIL+6.49%USOIL+6.40%XPTUSD-6.24%GAGUSD-5.47%XAGUSD-5.47%HG1-4.78%GAUUSD-1.92%XAUUSD-1.92%XNGUSD+1.68%SUGAR0.00%S10.00%COFFEE0.00%BTCUSD-1.32%ETHUSD-0.21%USDTUSD-0.02%XRPUSD-2.96%SOLUSD-1.53%TRXUSDT+0.12%ZECUSDT-9.33%DOGEUSD-2.24%XMRUSDT+0.03%LINKUSD-1.68%XLMUSD-1.77%BCHUSDT-9.71%LTCUSD-1.57%UNIUSD-1.34%TONUSD+24.88%HBARUSDT-1.85%SUIUSD-3.99%TAOUSDT-5.72%AAVEUSD-2.22%DOTUSDT-1.47%ICPUSDT+1.08%ONDOUSDT-3.31%WLDUSDT-3.15%ATOMUSDT-2.16%ARBUSDT-1.88%JUPUSDT-2.53%INJUSDT-2.62%STXUSDT-4.53%FETUSDT-2.47%TIAUSDT-1.39%PYTHUSDT-1.26%SEIUSDT-6.02%IMXUSDT-3.85%WIFUSDT-4.89%GRTUSDT-3.53%OPUSDT-3.00%POLUSDT-4.85%IOTAUSDT-4.24%AXSUSDT-2.36%FARTCOINUSDT-3.35%EOSUSDT-2.29%DYDXUSDT-1.75%ORDIUSDT-1.01%GALAUSDT-3.65%NOTUSDT-2.97%RONINUSDT-2.64%
VP

Vanda Pharmaceuticals Inc. (VNDA)

NASDAQ • Healthcare

$5.04
-$0.2 (-4.0%)
Market closed

Last close at September 10, 2026 at 20:00 UTC

Open$5.2
Day Range$5.01 - $5.2
Avg. Volume (3M)780.2K
Market Cap$303.6M
52 Week Range
$4.27$9.94
Next EarningsIn 55 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$50.5M100%
Gross Profitminus cost of goods$46.9M93%

Fundamentals & Financials

Revenue (TTM)
$215.7M
Net Income (TTM)
-$274.8M
EPS (TTM)
-$4.63
ROA (TTM)
-66.64%
Current Ratio
1.61

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-9.6%Q1 2026-$2.39
-54.7%Q2 2026-$0.82
-78.5%Q3 2026-$1.04
Next

Nov 4

in 55 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -78.5%

Vanda Pharmaceuticals’ results trailed consensus on both the top and bottom line, as revenue missed estimates despite only a modest year-over-year dip; the company’s second fiscal quarter of 2026, reported August 5, 2026, generated revenue down 3.9% to about $50.5 million (from about $52.6 million a year ago) while EPS of -$1.04 trailed the -$0.58 estimate by -$0.46, and revenue of $50.5 million trailed the $61.9 million estimate (-18.4%). Gross profit came in at roughly $47.0 million, with gross margin near 93%, but operating income was -about $63.8 million and operating margin was around -126%, pointing to operating costs outweighing the quarter’s gross profit base. Net income was down 129.8% year over year to roughly -$62.5 million (versus about -$27.2 million a year ago), alongside EPS down 126.1% from -$0.46. The company’s marketed portfolio includes HETLIOZ and Fanapt. For the next period, consensus calls for EPS of -$0.72 on revenue of $69.3 million.

View full earnings history

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. develops and commercializes therapies for unmet medical needs in Biotechnology and trades on the NASDAQ as VNDA. Its marketed portfolio centers on HETLIOZ for non-24-hour sleep-wake disorder and Fanapt oral tablets for schizophrenia, and it generated $216.1 million of revenue in FY2025.

Name
Vanda Pharmaceuticals Inc.
CEO
Mihael H. Polymeropoulos
Website
www.vandapharma.com
Industry
Healthcare
Year Founded
2002
Employees
533

Today's Snapshot

AI-generated

VNDA closed 4% below yesterday's close, in line with a weaker sector. Volume was about a quarter more than its usual level.

Trading Volume

Above 10d avg 663.7K

901K

vs S&P 500 Today

Strong Underperformance

-3.43%

Updated: September 10, 2026 at 20:07 UTC

Technical Indicators

1 Buy1 Neutral6 Sell
VNDA is exhibiting clear technical weakness as the stock trades near 5.02 and sits below most short-, medium- and long-term moving averages while VWAP and the pivot point remain marginally above the market. Momentum measures are unfavorable: CCI is deeply negative and MACD is slightly bearish, with RSI in the lower range indicating limited upside. ADX shows only a modest trend, ATR reflects moderate intraday range, and OBV points to net distribution. Taken together these factors support the overall strong-sell stance. Technical takeaway: Strong Sell — price beneath key averages with weak momentum, muted trend and negative volume.
All signals
  • EMA (5 indicators)$5.30 - $6.02
    Sell
  • RSI (14)39.81
    Neutral
  • Stochastic %K (14, 3, 3)13.92
    Buy
  • MACD Level (12, 26)-0.04
    Sell

Peers & Related Assets

ALLOAllogene Therapeutics, Inc.
$1.76+1.7%
CAPRCapricor Therapeutics, Inc.
$8.3-3.9%
AVIRAtea Pharmaceuticals, Inc.
$5.18-1.7%
ARCTArcturus Therapeutics Holdings Inc.
$13.98-5.2%
TRDAEntrada Therapeutics, Inc.
$6.42-9.7%
VYGRVoyager Therapeutics, Inc.
$3.19-1.9%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.